Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 15/20 | 1.00 |
| ▸ | PKN2 | Q16513 | 2/20 | 1.00 |
| ▸ | PRKG1 | Q13976 | 2/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.58 |
| ▸ | ITGA2 | P17301 | 2/20 | 0.58 |
| ▸ | MELK | Q14680 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | PLG | P00747 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 1/20 | 0.52 |
| ▸ | PLAT | P00750 | 1/20 | 0.52 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30589646 | 1.00 | ROCK2 (1.00) | ROCK2PKN2PRKG1PRKCECYP3A4 | |
| SCHEMBL321037 | 0.92 | ROCK2 (0.84) | ROCK2PKN2PRKG1PRKCECYP3A4 | |
| SCHEMBL307412 | 0.88 | ROCK2 (1.00) | ROCK2PKN2PRKG1PRKCECYP3A4 | |
| SCHEMBL10198161 | 0.88 | ROCK2 (0.78) | ROCK2PKN2PRKG1PRKCECYP3A4 | |
| SCHEMBL307784 | 0.84 | ROCK2 (0.93) | ROCK2PKN2PRKG1PRKCECYP3A4 | |
| SCHEMBL14135086 | 0.83 | ROCK2 (0.71) | ROCK2PKN2PRKG1PRKCECYP3A4 | |
| SCHEMBL306920 | 0.83 | ROCK2 (0.85) | ROCK2PKN2PRKG1PRKCECYP3A4 | |
| SCHEMBL306708 | 0.82 | ROCK2 (1.00) | ROCK2PKN2PRKG1PRKCECYP3A4 | |
| Hydrochloric Acid SCHEMBL309083 | 0.81 | ROCK2 (0.98) | ROCK2PKN2PRKG1PRKCECYP3A4 | |
| SCHEMBL307523 | 0.80 | ROCK2 (0.82) | ROCK2PKN2PRKG1PRKCECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3843845-B1 | INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA | UNIV MASSACHUSETTS (US) | 2026-03-11 | — | — | EP | claimed |
| US-12281308-B2 | Inhibition of protein kinases to treat Friedreich ataxia | UNIVERSITY OF MASSACHUSETTS (US) | 2025-04-22 | — | — | US | claimed |
| EP-3371211-B1 | RHO-ASSOCIATED PROTEIN KINASE (\"ROCK\") INHIBITOR FOR TREATING TUMORS AND CANCER, AND IDENTIFYING CANDIDATE SUBJECTS FOR SUCH TREATMENT | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-01-01 | — | — | EP | claimed |
| US-20230364062-A1 | METHOD OF TREATING MYELOID MALIGNANCIES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-11-16 | — | — | US | claimed |
| EP-4228637-A1 | METHOD OF TREATING MYELOID MALIGNANCIES | Yeda Research and Development Co. Ltd (IL) | 2023-08-23 | — | — | EP | claimed |
| WO-2022079719-A1 | METHOD OF TREATING MYELOID MALIGNANCIES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-04-21 | — | — | WO | claimed |
| US-11273151-B2 | Methods of treating tumors and cancer, and identifying candidate subjects for such treatment | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-03-15 | — | — | US | claimed |
| EP-3843845-A1 | INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA | University Of Massachusetts (US) | 2021-07-07 | — | — | EP | claimed |
| WO-2020047229-A1 | INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA | UNIVERSITY OF MASSACHUSETTS (US) | 2020-03-05 | — | — | WO | claimed |
| EP-3843845-B1 | INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA | UNIV MASSACHUSETTS (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12281308-B2 | Inhibition of protein kinases to treat Friedreich ataxia | UNIVERSITY OF MASSACHUSETTS (US) | 2025-04-22 | — | — | US | disclosed |
| EP-3371211-B1 | RHO-ASSOCIATED PROTEIN KINASE (\"ROCK\") INHIBITOR FOR TREATING TUMORS AND CANCER, AND IDENTIFYING CANDIDATE SUBJECTS FOR SUCH TREATMENT | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240173358-A1 | Compositions and Methods for the Treatment of Conditions Associated with Nucleotide Repeat Expansion | THE GENERAL HOSPITAL CORPORATION | 2024-05-30 | — | — | US | disclosed |
| EP-4308153-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NUCLEOTIDE REPEAT EXPANSION | The General Hospital Corporation (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-2114869-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
| WO-2008086047-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041645-A1 | RHO KINASE INHIBITORS | CIT, ROCK1, RHOT2 | ROCK2 4/4885PKN2 332/4885PRKG1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.